Edition:
United Kingdom

Tenax Therapeutics Inc (TENX.OQ)

TENX.OQ on NASDAQ Stock Exchange Capital Market

0.33USD
21 Feb 2018
Change (% chg)

$-0.01 (-1.62%)
Prev Close
$0.34
Open
$0.34
Day's High
$0.34
Day's Low
$0.33
Volume
7,386
Avg. Vol
56,740
52-wk High
$0.84
52-wk Low
$0.30

Latest Key Developments (Source: Significant Developments)

Tenax Therapeutics Announces Plan To Develop Levosimendan For A Pulmonary Hypertension Indication With No FDA Approved Therapies
Tuesday, 16 Jan 2018 

Jan 16 (Reuters) - Tenax Therapeutics Inc ::TENAX THERAPEUTICS ANNOUNCES PLAN TO DEVELOP LEVOSIMENDAN FOR A PULMONARY HYPERTENSION INDICATION WITH NO FDA APPROVED THERAPIES.TENAX THERAPEUTICS - PHASE 2 TRIAL TO INVESTIGATE LEVOSIMENDAN IN PULMONARY HYPERTENSION-WHO GROUP 2 PATIENTS WITH PRESERVED EJECTION FRACTION.TENAX THERAPEUTICS INC - PLANS TO INITIATE PHASE 2 TRIAL IN PH-HFPEF PATIENTS IN EARLY PART OF Q3 OF 2018.TENAX THERAPEUTICS INC - ‍PRE-IND MEETING IS SCHEDULED WITH FDA TO DISCUSS DEVELOPMENT OF LEVOSIMENDAN IN PH-HFPEF IN COMING MONTHS​.  Full Article

Tenax Therapeutics q2 loss per share $0.17
Thursday, 11 Aug 2016 

Tenax Therapeutics Inc : Tenax therapeutics announces second quarter 2016 financial results and provides corporate update . Q2 loss per share $0.17 . Currently anticipates that its cash balance at end of 2016 will be between $19 million and $20 million .Continues to expect that its cash balance will be sufficient for it to accomplish its corporate goals through 2017.  Full Article

Tenax Therapeutics Q1 loss per share $0.19
Thursday, 19 May 2016 

Tenax Therapeutics Inc : Continues to expect that its cash balance will be sufficient for it to accomplish its corporate goals through 2017 . Tenax therapeutics announces first quarter 2016 financial results and provides corporate update .Q1 loss per share $0.19.  Full Article

BRIEF-Tenax Therapeutics Announces Plan To Develop Levosimendan For A Pulmonary Hypertension Indication With No FDA Approved Therapies

* TENAX THERAPEUTICS ANNOUNCES PLAN TO DEVELOP LEVOSIMENDAN FOR A PULMONARY HYPERTENSION INDICATION WITH NO FDA APPROVED THERAPIES